Technology | October 14, 2011

Hologic Features Next Generation Multi-lumen Brachytherapy Applicator

Should cancer be detected in its early stages, many women are candidates for Hologic's targeted radiation therapy, a patient-friendly and effective alternative for women that qualify. At RSNA 2011, Hologic will feature its next generation MammoSite multi-lumen (ML) brachytherapy applicator.

For women with early-stage breast cancer, Hologic offers today’s most widely used form of partial breast irradiation: MammoSite five-day targeted radiation therapy. MammoSite therapy gives physicians an important tool for the practice of breast-conserving therapy, and it makes it easier for more women to consider the choice of lumpectomy, including some women who may have otherwise had a mastectomy to avoid lengthy conventional radiation therapy. Hologic continues to expand the horizon of Accelerated Partial Breast Irradiation (APBI) for early-stage breast cancer patients with its next generation MammoSite multi-lumen (ML) brachytherapy applicator. The MammoSite ML technology enables the ability to shift the radiation dose for a more precise target. This feature will result in more women being appropriate candidates for APBI.

For more information: www.hologic.com

Related Content

Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
News | Brachytherapy Systems, Women's Healthcare | October 25, 2018
iCAD Inc. announced new clinical research demonstrating positive outcomes supporting the use of the Xoft Axxent...
Xoft Electronic Brachytherapy System Effective Long-Term for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 02, 2018
Breast cancer recurrence rates for patients treated with the Xoft Axxent Electronic Brachytherapy (eBx) System that...